Dalpiciclib Clinical Trials
10 recruitingDrug
Phase 28Phase 31
Showing 1–10 of 10 trials
Recruiting
Phase 2
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Breast Cancer
Hebei Medical University Fourth Hospital60 enrolled1 locationNCT07492394
Recruiting
Phase 3
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.312 enrolled2 locationsNCT07207070
Recruiting
Phase 2
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）
Breast Cancer
Hebei Medical University Fourth Hospital144 enrolled1 locationNCT06107673
Recruiting
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer
Breast Cancer
Hebei Medical University Fourth Hospital420 enrolled1 locationNCT05578053
Recruiting
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Breast CancerBreast NeoplasmBreast Tumors
Fudan University716 enrolled1 locationNCT05582499
Recruiting
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Breast CancerBreast NeoplasmHER2-negative Breast Cancer+2 more
Fudan University620 enrolled1 locationNCT05594095
Recruiting
Phase 2
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University1,163 enrolled1 locationNCT06341894
Recruiting
Phase 2
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
Breast Cancer Metastatic
Fudan University145 enrolled1 locationNCT05759572
Recruiting
Phase 2
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Breast Cancer Metastatic
Fudan University200 enrolled1 locationNCT05759546
Recruiting
Phase 2
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Breast Cancer
Shengjing Hospital236 enrolled1 locationNCT05638594